证券代码：002919 证券简称：名臣健康 公告编号：2025-003 名臣健康用品股份有限公司 第四届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 名臣健康用品股份有限公司(以下简称"公司")第四届董事会第四次会议于 2025年4月28日在公司二楼会议室以现场和视频通讯方式召开，会议通知以专人 送达、传真、电子邮件、电话相结合的方式已于2025年4月18日向各位董事发出。 本次会议由董事长兼总经理陈建名先生主持。本次会议应出席董事7名，实际出 席董事7名(其中：董事梁锦辉先生、独立董事高慧先生、陈景华先生、吴小艳女 士以通讯方式参会)，公司监事列席会议。本次会议的召开符合《公司法》、《公 司章程》等法律法规的规定，合法有效。 二、 董事会会议审议情况 1、审议通过《关于<2024 年度董事会工作报告>的议案》 表决结果：有效表决 7 票，同意票 7 票，反对票 0 票，弃权票 0 票。 经审核，董事会认为，2024 年度公司全体董事严格按照《公司法》相关法 律法规的要求和《公司章程》、《董事会议事规则》等制 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 361,419,226.73, a slight decrease of 0.10% compared to CNY 361,783,077.71 in the same period last year[5]. - Net profit attributable to shareholders decreased by 71.62% to CNY 12,713,011.49 from CNY 44,792,608.81 year-on-year[5]. - Basic and diluted earnings per share dropped by 70.59% to CNY 0.05 from CNY 0.17 in the same quarter last year[5]. - Operating profit decreased to ¥14,774,308.45, down 69.4% from ¥48,268,573.56 in the previous period[22]. - Net profit for the current period is ¥12,747,632.76, a significant decline of 71.5% from ¥44,792,608.81 in the previous period[22]. Cash Flow - The net cash flow from operating activities was negative CNY 52,846,010.99, a decline of 70.72% compared to negative CNY 30,954,318.55 in the previous year[13]. - Cash inflow from operating activities totaled ¥267,700,532.63, down from ¥284,521,640.80 in the previous period[24]. - The net cash flow from investment activities was -$1.71 million, improving from -$22.17 million year-over-year[25]. - Total cash outflow from operating activities was $320.55 million, compared to $315.48 million previously, showing stable operational cash outflows[25]. Assets and Liabilities - Total assets increased by 1.49% to CNY 1,119,796,609.12 from CNY 1,103,346,118.01 at the end of the previous year[5]. - The total current assets are 661,593,066.07 yuan, down from 690,847,376.26 yuan at the beginning of the period[18]. - The total liabilities include accounts payable of 152,860,463.00 yuan, which increased from 127,066,568.53 yuan, a rise of about 20.3%[18]. - Total liabilities increased to ¥283,712,534.47 from ¥280,009,676.12 in the previous period[19]. Operating Costs and Expenses - The company reported a 27.34% increase in operating costs, rising to CNY 157,926,236.96 from CNY 124,018,992.61, primarily due to the launch of multiple games[11]. - Total operating costs increased to ¥340,518,894.23, up 10.9% from ¥306,836,632.03 in the previous period[21]. - Research and development expenses decreased by 30.34% to CNY 13,676,400.02 from CNY 19,631,760.74, attributed to project optimization and team streamlining[11]. - Research and development expenses decreased to ¥13,676,400.02, down 30.5% from ¥19,631,760.74 in the previous period[22]. Shareholder Information - The company's total equity attributable to shareholders increased by 1.54% to CNY 836,051,909.31 from CNY 823,338,897.82 at the end of the previous year[5]. - The total number of common shareholders at the end of the reporting period is 18,272[14]. - The largest shareholder, Chen Qinfang, holds 35.02% of shares, totaling 93,338,604 shares, with 11,644,000 shares pledged[14]. Other Information - The company has no preferred shareholders as of the reporting period[16]. - The first quarter report was not audited, which may affect the reliability of the financial data presented[27]. - The company plans to adopt new accounting standards starting in 2025, which may impact future financial reporting[26]. - The company did not execute any significant acquisitions or new product launches during this reporting period[27].

Financial Performance - The company's revenue for 2024 was CNY 1,380,254,020.51, a decrease of 15.71% compared to CNY 1,637,567,748.39 in 2023[16]. - Net profit attributable to shareholders for 2024 was CNY 46,719,608.82, down 33.60% from CNY 70,364,740.74 in 2023[16]. - The net profit after deducting non-recurring gains and losses was CNY 45,983,843.85, a decrease of 29.50% from CNY 65,229,683.42 in 2023[16]. - Basic earnings per share for 2024 were CNY 0.18, a decline of 30.77% compared to CNY 0.26 in 2023[16]. - Total assets at the end of 2024 were CNY 1,103,346,118.01, a decrease of 13.40% from CNY 1,274,031,659.57 at the end of 2023[16]. - Net assets attributable to shareholders increased by 1.66% to CNY 823,338,897.82 from CNY 809,886,297.25 at the end of 2023[16]. - The revenue from daily chemical products was CNY 402,760,889.45, representing 29.18% of total revenue, a decline of 14.31% from the previous year[36]. - Revenue from the online gaming segment was CNY 973,204,805.49, accounting for 70.51% of total revenue, down 16.40% year-on-year[36]. Cash Flow and Investments - Operating cash flow net amount increased by 138.45% to CNY 165,276,242.39 from CNY 69,314,099.52 in 2023[16]. - The net cash flow from operating activities in Q4 2023 was approximately CNY 108.60 million, a substantial increase compared to a negative cash flow of approximately CNY 30.95 million in Q1 2023[20]. - Total cash inflow from operating activities decreased by 18.56% to ¥1,248,071,078.58 in 2024, while cash outflow decreased by 26.00% to ¥1,082,794,836.19[51]. - Net cash flow from investment activities dropped significantly by 774.88% to -¥105,659,688.83, mainly due to the purchase of financial products[53]. - Cash and cash equivalents increased by only ¥2,474,448.11 in 2024, a decline of 91.90% compared to the previous year[52]. Business Strategy and Market Position - The company has shifted its business model to include both daily chemical products and online gaming, indicating a strategic expansion[14]. - The company is focusing on diversifying sales channels, including e-commerce and live streaming, to enhance market competitiveness and mitigate risks associated with single-channel operations[26]. - The company plans to invest in new product development and technology to meet the increasing demand for personalized and high-quality daily chemical products[27]. - The company is currently developing three major projects aimed at transforming and expanding its product lines, with positive impacts expected on future revenue[46]. - The company will focus on developing high-quality games and improving product longevity, with plans to enter new overseas markets in 2024[72]. Research and Development - The number of R&D personnel decreased by 57.97% from 345 in 2023 to 145 in 2024, with a corresponding drop in the proportion of R&D personnel from 22.26% to 11.44%[49]. - R&D investment amounted to ¥69,410,518.02 in 2024, a decrease of 37.62% compared to ¥111,267,763.02 in 2023, with the R&D investment as a percentage of operating revenue falling from 6.79% to 5.03%[49]. - The company holds 56 invention patents and has established itself as a leader in domestic daily chemical product technology[32]. - The company has a total of 117 copyright registrations in its gaming business, indicating strong intellectual property assets[33]. Governance and Shareholder Relations - The company has established a governance structure that ensures equal rights for all shareholders, particularly minority shareholders, in decision-making processes[81]. - The company emphasizes the importance of brand reputation and will actively monitor and protect its brand against infringement[74]. - The company has maintained a clear and transparent cash dividend policy, ensuring the protection of minority shareholders' rights[111]. - The annual shareholder meeting had a participation rate of 40.63%, with all proposed resolutions approved[87]. - The company has appointed independent directors to ensure compliance and oversight, with specific roles in various committees[94]. Subsidiaries and Market Expansion - The company established five new subsidiaries during the reporting period, including Hallgou Network Technology Co., Ltd. and Guangxi Tianniu Information Technology Co., Ltd.[42]. - The subsidiary Guangdong Mingchen Daily Chemical Co., Ltd. reported revenue of ¥405,131,496.53 and a net profit of ¥14,261,604.75 during the reporting period[66]. - The subsidiary Hainan Xingxuan Shikong Network Technology Co., Ltd. achieved revenue of ¥771,054,905.78 and a net profit of ¥108,126,314.63 in the reporting period[70]. Risk Management - The company acknowledges potential risks in its future operations as outlined in the management discussion section[4]. - The company is aware of risks related to brand image and competition in the gaming industry, and it has strategies in place to mitigate these risks[76]. Social Responsibility and Community Engagement - The company sponsored 150,000 yuan for a traditional cultural event and donated 120,000 yuan for a calligraphy competition, supporting cultural heritage and education[127]. - The company emphasizes a "people-oriented" approach, providing training and development opportunities for employees to enhance their skills[124]. Compliance and Internal Controls - The company has established a comprehensive internal control system that has been effectively implemented, with no significant defects identified in financial reporting[114]. - The internal control audit report indicates that the company maintained effective financial reporting internal controls as of December 31, 2024[119]. - The company has not identified any significant defects in internal controls related to non-financial reporting during the evaluation period[117].

证券代码：002919 证券简称：名臣健康 公告编号：2025-006 名臣健康用品股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、审议程序 名臣健康用品股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开 了第四届董事会第四次会议和第四届监事会第四次会议，审议通过了《关于<2024 年度利润分配预案>的议案》，本议案尚需提交公司 2024 年年度股东大会审议。 现将有关情况公告如下： 二、利润分配预案基本情况 1、年度现金分红方案相关指标 根据致同会计师事务所（特殊普通合伙）出具的《名臣健康用品股份有限公 司 2024 年度审计报告》（致同审字（2025）第 351A020765 号）显示，公司 2024 年实现归属母公司股东的净利润 46,719,608.82 元，母公司实现净利润为亏损 5,048,236.04 元。根据《公司法》和《公司章程》等相关规定，2024 年母公司 不提取法定盈余公积金，截至 2024 年 12 月 31 日，公司合并口径可供股东分配 的利润为 354, ...

注：本次质押股份未负担重大资产重组等业绩补偿义务。 名臣健康用品股份有限公司关于控股股东部分股份质押的公告 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002919 证券简称：名臣健康 公告编号：2025-001 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 名臣健康用品股份有限公司（以下简称"公司"）近日收到公司控股股东陈勤发先生的告知函，获悉陈勤 发先生将其所持公司部分股份办理了质押手续，具体事项如下： 一、股东股份质押基本情况 ■ 三、备查文件 1、证券质押登记证明； 2、中国证券登记结算有限责任公司证券质押明细表； 3、告知函。 二、股东股份累计质押的基本情况 截至本公告披露日, 陈勤发先生所持质押股份情况： ■ 注：上表中若出现总计数与所列数值总和不符，均为四舍五入所致。 截至本公告披露日，陈勤发先生持有公司93,338,604股股份，占公司总股本的35.02%，其中累计质押的 股份数为11,644,000股，占其持有公司股份总数的12.48%，占公司总股本的4.37%。陈勤发先生累计质 押股份不存在被强制平仓风险，亦不会对公司生产 ...

一、股东股份质押基本情况 证券代码：002919 证券简称：名臣健康 公告编号：2025-001 名臣健康用品股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 名臣健康用品股份有限公司（以下简称"公司"）近日收到公司控股股东陈 勤发先生的告知函，获悉陈勤发先生将其所持公司部分股份办理了质押手续，具 体事项如下： | 股东 | 是否为控股 | | | | | 是否 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股东或第一 | 本次质押股 | 占其所 持股份 | 占公司 总股本 | 是否 为限 | 为补 | 质押起始 | | 质押到 | 质权 | 质押 | | 名称 | 大股东及其 | 份数量（股） | 比例 | 比例 | 售股 | 充质 | 日 | | 期日 | 人 | 用途 | | | 一致行动人 | | | | | 押 | | | | | | | 陈勤 | | | | | | | 2 ...

证券代码：002919 证券简称：名臣健康 公告编号：2024-039 名臣健康用品股份有限公司 关于设立全资孙公司的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 名臣健康用品股份有限公司（以下简称"公司"）于2024年10月29日召开了 公司第四届董事会第三次会议，审议通过了《关于全资子公司拟投资设立孙公司 的议案》，同意公司子公司广东名臣日化有限公司拟投资500万元在广州独资设立 孙公司名臣日化电子商务有限公司（暂定名）（以下简称"孙公司"）。具体内 容详见公司于2024年10月30日在《证券日报》、《证券时报》、《中国证券报》、《上 海证券报》和巨潮资讯网（www.cninfo.com.cn）披露的《第四届董事会第三次 会议决议公告》（公告编号：2024-036）。 近日，孙公司完成了工商登记手续并取得由广州市白云区市场监督管理局正 式核准颁发的《营业执照》，具体信息如下： 1、公司名称：广州名臣智易网络有限公司 7、成立日期：2024 年 11 月 19 日 8、营业期限：长期 9、经营范围：互联网数据服务；技术进出口；货物进出口；化妆品零 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 名臣健康用品股份有限公司（以下简称"公司"）于近日接到持股 5%以上 股东吴心玲女士的通知，获悉吴心玲女士将其所持有的部分公司股份办理了补充 质押，具体事项如下： | 股东名称 | 是否为控股 股东或第一 | 本次质押股 | 占其所 | 占公司 | 是否 | 是否 为补 | | 质押到 | | 质押用 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 持股份 | 总股本 | 为限 | | 质押起始 | | 质权人 | | | | 大股东及其 | 份数量（股） | | | | 充质 | | 期日 | | 途 | | | | | 比例 | 比例 | 售股 | | | | | | | | 一致行动人 | | | | | 押 | | | | | | | | | | | | | 2024 年 11 | 解除质 | 招商证券 | 补充质 | | 吴心玲 | 否 | 1,280,000 | 8.73% | 0.48% | ...

名臣健康用品股份有限公司(以下简称"公司")第四届董事会第三次会议于 2024年10月29日在公司子公司喀什奥术网络科技有限公司会议室以现场方式召 开，会议通知以专人送达、传真、电子邮件、电话相结合的方式已于2024年10 月25日向各位董事发出。本次会议由董事陈建名先生主持。本次会议应出席董事 7名，实际出席董事7名，公司监事列席会议。本次会议的召开符合《公司法》、 《公司章程》等法律法规的规定，合法有效。 二、董事会会议审议情况 1、审议通过《关于<2024 年第三季度报告>的议案》 名臣健康用品股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：002919 证券简称：名臣健康 公告编号：2024-036 表决结果：有效表决 7 票，同意票 7 票，反对票 0 票，弃权票 0 票。 经审核，董事会认为，公司 2024 年第三季度报告的内容真实、准确、完整 地反映了公司 2024 年第三季度经营的实际情况，不存在任何虚假记载、误导性 陈述或重大遗漏。 具体内容详见公司在《证券日报》 ...

证券代码：002919 证券简称：名臣健康 | --- | --- | --- | |-----------------------|-------------------------------------------|-------------------------------------------------------------------------------------| | | | | | | □特定对象调研 | □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | 其他（ 2024 | 广东辖区上市公司投资者集体接待日） | | 参与单位名称 | 投资者网上提问 | | | 时间 | 2024年9月12日15:30-16:30 | | | 方式 | | 公司通过全景网"投资者关系互动平台" (https://ir.p5w.net) | | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 员姓名 | 公司董事长、总经理陈建名 | 公司副董事长、副总经理、财务总监彭小 ...